AB Science S.A. (0Q77.L)
EUR 0.87
(-6.75%)
EUR 0.87
(-6.75%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 14.01 Million EUR | -16.89% |
| 2022 | 16.86 Million EUR | 10.2% |
| 2021 | 15.3 Million EUR | -5.9% |
| 2020 | 16.26 Million EUR | -13.79% |
| 2019 | 18.86 Million EUR | -37.94% |
| 2018 | 30.39 Million EUR | 1.25% |
| 2017 | 30.02 Million EUR | -3.96% |
| 2016 | 31.26 Million EUR | 12.01% |
| 2015 | 27.9 Million EUR | 65.06% |
| 2014 | 16.9 Million EUR | 9.99% |
| 2013 | 15.37 Million EUR | 31.24% |
| 2012 | 11.71 Million EUR | 11.35% |
| 2011 | 10.52 Million EUR | -10.19% |
| 2010 | 11.71 Million EUR | -11.61% |
| 2009 | 13.25 Million EUR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 4.85 Million EUR | 0.0% |
| 2023 Q3 | 733 Thousand EUR | -92.55% |
| 2023 Q4 | 2.46 Million EUR | 236.77% |
| 2023 FY | 14.01 Million EUR | -16.89% |
| 2023 Q1 | 4.89 Million EUR | -47.15% |
| 2023 Q2 | 9.83 Million EUR | 100.8% |
| 2022 Q3 | 3.39 Million EUR | -68.93% |
| 2022 Q2 | 10.93 Million EUR | 215.91% |
| 2022 Q1 | 3.46 Million EUR | -61.06% |
| 2022 FY | 16.86 Million EUR | 10.2% |
| 2022 Q4 | 9.27 Million EUR | 172.95% |
| 2021 Q2 | 8.55 Million EUR | 213.73% |
| 2021 Q1 | 2.72 Million EUR | -71.57% |
| 2021 FY | 15.3 Million EUR | -5.9% |
| 2021 Q4 | 8.88 Million EUR | 70.17% |
| 2021 Q3 | 5.22 Million EUR | -38.97% |
| 2020 Q2 | 8.82 Million EUR | 86.21% |
| 2020 Q3 | 3.47 Million EUR | -60.64% |
| 2020 FY | 16.26 Million EUR | -13.79% |
| 2020 Q1 | 4.74 Million EUR | -45.72% |
| 2020 Q4 | 9.59 Million EUR | 176.08% |
| 2019 Q2 | 13.17 Million EUR | 134.3% |
| 2019 FY | 18.86 Million EUR | -37.94% |
| 2019 Q1 | 5.62 Million EUR | -10.02% |
| 2019 Q4 | 8.73 Million EUR | 47.2% |
| 2019 Q3 | 5.93 Million EUR | -54.97% |
| 2018 Q2 | 7.5 Million EUR | 0.0% |
| 2018 Q1 | 7.5 Million EUR | 5.68% |
| 2018 FY | 30.39 Million EUR | 1.25% |
| 2018 Q4 | 6.25 Million EUR | 0.0% |
| 2018 Q3 | 6.25 Million EUR | -16.77% |
| 2017 FY | 30.02 Million EUR | -3.96% |
| 2017 Q4 | 7.1 Million EUR | 0.0% |
| 2017 Q1 | 7.27 Million EUR | 10.26% |
| 2017 Q2 | 7.27 Million EUR | 0.0% |
| 2017 Q3 | 7.1 Million EUR | -2.26% |
| 2016 Q4 | 6.59 Million EUR | 0.0% |
| 2016 Q3 | 6.59 Million EUR | -12.93% |
| 2016 Q1 | 7.57 Million EUR | 7.44% |
| 2016 FY | 31.26 Million EUR | 12.01% |
| 2016 Q2 | 7.57 Million EUR | 0.0% |
| 2015 FY | 27.9 Million EUR | 65.06% |
| 2015 Q2 | 6.78 Million EUR | 0.0% |
| 2015 Q4 | 7.04 Million EUR | 0.0% |
| 2015 Q3 | 7.04 Million EUR | 3.89% |
| 2015 Q1 | 6.78 Million EUR | 46.03% |
| 2014 Q4 | 4.64 Million EUR | 0.0% |
| 2014 FY | 16.9 Million EUR | 9.99% |
| 2014 Q1 | 3.79 Million EUR | -9.9% |
| 2014 Q2 | 3.79 Million EUR | 0.0% |
| 2014 Q3 | 4.64 Million EUR | 22.35% |
| 2013 Q2 | 3.54 Million EUR | 0.0% |
| 2013 Q3 | 4.21 Million EUR | 18.94% |
| 2013 Q4 | 4.21 Million EUR | 0.0% |
| 2013 FY | 15.37 Million EUR | 31.24% |
| 2013 Q1 | 3.54 Million EUR | 0.0% |
| 2012 FY | 11.71 Million EUR | 11.35% |
| 2011 FY | 10.52 Million EUR | -10.19% |
| 2010 FY | 11.71 Million EUR | -11.61% |
| 2009 FY | 13.25 Million EUR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Boiron SA | 317.27 Million EUR | 95.582% |
| Laboratorios Farmaceuticos Rovi, S.A. | 263.09 Million EUR | 94.673% |
| Vetoquinol SA | 217.11 Million EUR | 93.544% |
| Valneva SE | 134.92 Million EUR | 89.612% |
| Nanobiotix S.A. | 62.98 Million EUR | 77.748% |
| PHAXIAM Therapeutics S.A. | 24.98 Million EUR | 43.905% |
| Vivoryon Therapeutics N.V. | 24.69 Million EUR | 43.237% |
| BioSenic S.A. | 7.58 Million EUR | -84.834% |
| ABIVAX Société Anonyme | 127.37 Million EUR | 88.996% |
| Formycon AG | 23.73 Million EUR | 40.943% |